Dr. Fredrik Lindberg is a Board Member of Sigrid Therapeutics AB, as well as a serial entrepreneur within the life science industry.
Dr. Lindberg is an experienced CEO with a strong background in business development. He is the CEO of AGB Pharma since May 2020, a company developing a melatonin approved treatment for insomnia in children with ADHD and Board Member of Enzymatica AB. Previous engagements are CEO of Enzymatica 2014-2020, founder of BoneSupport AB 2001 – 2014, and Nordic Medical Director at Searle Pharmaceuticals.
Dr. Fredrik Lindberg is an MD, Ph.D., and Assoc. Prof in Clinical Pharmacology from Lund University, Sweden.